Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$154.05 USD

154.05
378,892

+4.29 (2.87%)

Updated Nov 4, 2024 10:27 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher

Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    Alexion's Soliris Successful in Phase III Study for NMOSD

    Alexion's (ALXN) efforts to expand lead blockbuster drug Soliris' label gets a boost as the phase III study on the drug for the indication of NMSOD was successful.

      AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session

      AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

        Is First Trust Multi Cap Growth AlphaDEX Fund (FAD) a Hot ETF Right Now?

        Smart Beta ETF report for FAD

          Nalak Das headshot

          Major Stock Indexes Approaching Record Highs: 5 Top Picks

          The three major stock market indexes ??? the Dow 30, S&P 500 and Nasdaq Composite ??? are at present within the striking distance to achieve their all-time high level.

            Cytori's Chemotherapy Candidate Gets Orphan Drug Status

            Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

              AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology

              AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.

                The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

                The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

                  DENTSPLY Launches Azento, Improves Digital Implant Workflow

                  DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.

                    Nitish Marwah headshot

                    IPOs and Foreign Investment Propel Biotech: 4 Top Picks

                    A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.

                      Nabaparna Bhattacharya headshot

                      Allscripts' Sunrise Abstracting Selected by Wyckoff Heights

                      Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.

                        Is Illumina (ILMN) Stock Outpacing Its Medical Peers This Year?

                        Is (ILMN) Outperforming Other Medical Stocks This Year?

                          Sweta Killa headshot

                          Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

                          Sector ETF report for ARKG

                            Here's Why You Should Hold On to DaVita (DVA) Stock Now

                            Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.

                              Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit

                              BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.

                                OPKO Health (OPK) Begins RAYALDEE Phase 2 Clinical Trial

                                OPKO Health's (OPK) consistent focus on enhancing the efficacy of its flagship RAYALDEE platform is likely to lend it a competitive edge in the MedTech space.

                                  Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine

                                  Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.

                                    ProQR Up More Than 120% on Favorable Eye Disorder Study Data

                                    ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

                                      Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx

                                      Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

                                        Neogen's Livestock Genetic Buyout Expands Animal Safety Suite

                                        The acquisition of Livestock Genetic will position Neogen (NEOG) as a leading agrigenomics company worldwide.

                                          MannKind Stock Up on Licensing Deal With United Therapeutics

                                          MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

                                            HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates

                                            Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.

                                              Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

                                              Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.

                                                Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries

                                                Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries

                                                  Here's Why You Should Hold On to Baxter (BAX) Stock Now

                                                  Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.